Michael P. Gustafson

4.0k citations

67 papers · 2.8k indexed · 1 hit paper · h-index 28

Oncology top 2%
Immunology top 2%
Molecular Biology top 10%
Genetics top 2%
Epidemiology top 10%

Co-authors: Allan B. Dietz Dennis A. Gastineau Yi Lin Peggy A. Bulur Svetlana Bornschlegl April Mengos Mabel Ryder Thomas E. Witzig
Topics: Immunotherapy and Immune Responses (20 papers)Immune Cell Function and Interaction (19 papers)Cancer Immunotherapy and Biomarkers (15 papers)
Cited by: Immunology Oncology Genetics
Journals: Journal of Biological Chemistry Nature Medicine Journal of Clinical Oncology
Partner nations: United States United Kingdom France

In The Last Decade

Michael P. Gustafson

66 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

2024 132 citations Michael P. Gustafson et al. profile →

Peers

Countries citing papers authored by Michael P. Gustafson

Since Specialization

Citations

This map shows the geographic impact of Michael P. Gustafson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Gustafson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Gustafson more than expected).

Fields of papers citing papers by Michael P. Gustafson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Gustafson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Gustafson. The network helps show where Michael P. Gustafson may publish in the future.

Co-authorship network of co-authors of Michael P. Gustafson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Gustafson. A scholar is included among the top collaborators of Michael P. Gustafson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Gustafson. Michael P. Gustafson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers 2024 ·Cytotherapy ·(unknown),(unknown),(unknown),Gaurav Sutrave,(unknown),(unknown),(unknown),Michael P. Gustafson,Gloria B. Kim	1
2	Clinical utility of mesenchymal stem/stromal cells in regenerative medicine and cellular therapy 2023 ·Journal of Biological Engineering ·(unknown),Neel Patel,(unknown),C. Lowry Barnes,Michael P. Gustafson,Raj R. Rao,Rebekah M. Samsonraj	49
3	Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice 2023 ·Frontiers in Immunology ·Helena Batatinha,(unknown),Grace M. Niemiro,Forrest L. Baker,(unknown),(unknown),(unknown),Michael D. Seckeler,(unknown),Emily C. LaVoy,Michael P. Gustafson,Emmanuel Katsanis,Richard J. Simpson	10
4	COVID-19 vaccination produces exercise-responsive SARS-CoV-2 specific T-cells regardless of infection history 2023 ·Journal of sport and health science ·(unknown),(unknown),Forrest L. Baker,Helena Batatinha,Charles R. Pedlar,Shane C. Burgess,Michael P. Gustafson,Emmanuel Katsanis,Richard J. Simpson	2
5	Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma 2022 ·Neuro-Oncology Advances ·Ian F. Parney,S. Keith Anderson,Michael P. Gustafson,(unknown),Timothy E. Peterson,(unknown),Aditya Raghunathan,Brian Patrick O’Neill,Jan C. Buckner,(unknown),Allan B. Dietz	14
6	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction 2020 ·Neuro-Oncology ·Benjamin Himes,Timothy E. Peterson,(unknown),(unknown),Miyeon Jung,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Michael P. Gustafson,Allan B. Dietz,Aaron J. Johnson,Haidong Dong,(unknown),Svetomir N. Markovic,Fabrice Lucien,Ian F. Parney	76
7	Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations 2020 ·Thyroid ·Anupam Kotwal,Michael P. Gustafson,Svetlana Bornschlegl,Lisa A. Kottschade,Danae A. Delivanis,Allan B. Dietz,Manish J. Gandhi,Mabel Ryder	54
8	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine 2019 ·Clinical Cancer Research ·Keith L. Knutson,Matthew S. Block,Nadine Norton,Courtney L. Erskine,Timothy J. Hobday,Allan B. Dietz,Douglas Padley,Michael P. Gustafson,(unknown),(unknown),Saranya Chumsri,(unknown),Lavakumar Karyampudi,(unknown),Amy C. Degnim	11
9	The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy 2019 ·Frontiers in Immunology ·April Mengos,Dennis A. Gastineau,Michael P. Gustafson	104
10	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients 2018 ·Clinical Cancer Research ·Kimberly R. Kalli,Matthew S. Block,Pashtoon Murtaza Kasi,Courtney L. Erskine,Timothy J. Hobday,Allan B. Dietz,Douglas Padley,Michael P. Gustafson,Barath Shreeder,(unknown),(unknown),(unknown),(unknown),Keith L. Knutson	72
11	Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production 2016 ·Stem Cell Research & Therapy ·Emily T. Camilleri,Michael P. Gustafson,Amel Dudakovic,Scott M. Riester,(unknown),Christopher R. Paradise,Hideki Takai,Marcel Karperien,Simon M. Cool,(unknown),A. Noelle Larson,Wenchun Qu,Jay Smith,Allan B. Dietz,André J. van Wijnen	203
12	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma 2015 ·Clinical Cancer Research ·Michael P. Gustafson,Yi Lin,Jonathan Bleeker,Deepti Warad,Matthew K. Tollefson,Paul L. Crispen,Peggy A. Bulur,Susan M. Harrington,Rebecca R. Laborde,Dennis A. Gastineau,Bradley C. Leibovich,John C. Cheville,Eugene D. Kwon,Allan B. Dietz	38
13	Strategies for improving the reporting of human immunophenotypes by flow cytometry 2014 ·Journal for ImmunoTherapy of Cancer ·Michael P. Gustafson,Yi Lin,Mabel Ryder,Allan B. Dietz	11
14	Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity 2013 ·Cancer Immunology Research ·Rahul N. Chavan,(unknown),Michael P. Gustafson,Allan B. Dietz,Wendy K. Nevala,Svetomir N. Markovic	27
15	Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma 2012 ·Cancer Research ·Joachim C. Mertens,Christian D. Fingas,John D. Christensen,Rory L. Smoot,Steven F. Bronk,Nathan W. Werneburg,Michael P. Gustafson,Allan B. Dietz,Lewis R. Roberts,Alphonse E. Sirica,Gregory J. Gores	158
16	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties 2009 ·Neuro-Oncology ·Jennifer C. Rodrigues,G. C. Gonzalez,Lei Zhang,George M. Ibrahim,John J. Kelly,Michael P. Gustafson,Yi Lin,Allan B. Dietz,Peter Forsyth,V. Wee Yong,Ian F. Parney	200
17	Zcchc8 is a glycogen synthase kinase-3 substrate that interacts with RNA-binding proteins 2005 ·Biochemical and Biophysical Research Communications ·Michael P. Gustafson,Markus Welcker,Harry C. Hwang,Bruce E. Clurman	22
18	Differential Regulation of Growth and Checkpoint Control Mediated by a Cdc25 Mitotic Phosphatase from Pneumocystis carinii 2001 ·Journal of Biological Chemistry ·Michael P. Gustafson,Charles F. Thomas,Frank Rusnak,Andrew H. Limper,Edward B. Leof	21
19	Characterization of the Pneumocystis carinii Cyclin‐Dependent Kinase Life Cycle Regulatory System 1997 ·Journal of Eukaryotic Microbiology ·Andrew H. Limper,Charles F. Thomas,Kamal K. Mubarak,Michael P. Gustafson,Theodore J. Kottom,Edward B. Leof	4
20	Identification of a Cell Division Cycle (cdc2) Homologue in Pneumocystis carinii 1996 ·Journal of Eukaryotic Microbiology ·Charles F. Thomas,Michael P. Gustafson,Zvezdana Vuk-Pavlović,Edward B. Leof,Andrew H. Limper	5

About Michael P. Gustafson

Michael P. Gustafson is a scholar working on Immunology, Oncology and Rehabilitation, having authored 67 papers that have together received 2.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (20 papers), Immune Cell Function and Interaction (19 papers) and Cancer Immunotherapy and Biomarkers (15 papers). The work is most often cited by research in Immunology (1.2k citations), Oncology (1.3k citations) and Genetics (482 citations). Michael P. Gustafson has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Allan B. Dietz, Dennis A. Gastineau, Yi Lin, Peggy A. Bulur, Svetlana Bornschlegl, April Mengos, Mabel Ryder, Thomas E. Witzig, Danae A. Delivanis and Lisa A. Kottschade. Their work appears in journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact